Narcolepsy Therapeutics Market Analysis By Type (Cataplexy and Without Cataplexy), By Product (Central Nervous System Stimulants, Sodium Oxybate, Tricyclic Antidepressants)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

Chapter 1 Research Methodology & Scope
               1.1 Information Procurement
                   1.1.1 Purchased database:
                   1.1.2 Nova one advisor’s internal database
               1.2 Research Methodology
               1.3 Geographic scope & assumptions
               1.4 Region-wise market calculation
                   1.4.1 Region-wise market: Base estimates
                   1.4.2 Global market: CAGR calculation
               1.5 Region-based segment share calculation
               1.6 List of Secondary Sources
Chapter 2 Executive Summary
               2.1 Market Snapshot
Chapter 3 Narcolepsy Therapeutics Market Variables, Trends & Scope
               3.1 Market segmentation & scope
                   3.1.1 Market driver analysis
                       3.1.1.1 Increasing global prevalence of narcolepsy
                       3.1.1.2 Narcolepsy awareness programs and services
                       3.1.1.3 Presence of reimbursement policies regarding narcolepsy
                   3.1.2 Market restraint analysis
                       3.1.2.1 Adverse effects and risks related to narcolepsy drugs
                       3.1.2.2 Delayed diagnosis or misdiagnosis
               3.3 Narcolepsy therapeutics - SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
               3.4 Industry Analysis - Porter’s
Chapter 4 M Narcolepsy Therapeutics Market: Type Estimates & Trend Analysis
               4.1 Narcolepsy Therapeutics Market: Type Movement Analysis
               4.2 Narcolepsy With Cataplexy
                   4.2.1 Narcolepsy with cataplexy market, 2014 - 2025 (USD Million)
               4.3 Narcolepsy Without Cataplexy
                   4.3.1 Narcolepsy without cataplexy market, 2014 - 2025 (USD Million)
               4.4 Secondary Narcolepsy
                   4.4.1 Secondary narcolepsy market, 2014 - 2025 (USD Million)
Chapter 5 Narcolepsy Therapeutics Market: Product Estimates & Trend Analysis
               5.1 Narcolepsy Therapeutics Market: Product Movement Analysis
               5.2 Central nervous system stimulants
                   5.2.1 Central nervous system stimulants market, 2014 - 2025 (USD Million)
               5.3 Sodium Oxybate
                   5.3.1 Sodium Oxybate market, 2014 - 2025 (USD Million)
               5.4 Selective Serotonin Reuptake Inhibitor (SSRI)
                   5.4.1 Selective serotonin reuptake inhibitor market, 2014 - 2025 (USD Million)
               5.5 Tricyclic Antidepressants
                   5.5.1 Tricyclic antidepressants market, 2014 - 2025 (USD Million)
               5.6 Other Narcolepsy Drugs
                   5.6.1 Other narcolepsy drugs market, 2014 - 2025 (USD Million)
Chapter 6 Narcolepsy Therapeutics: Regional Estimates & Trend Analysis, by Drug Type
               6.1 Narcolepsy Therapeutics Market Share by Region, 2016 & 2025
               6.2 North America
                   6.2.1 North America narcolepsy therapeutics market, 2014 - 2025 (USD Million)
               6.3 Europe
                   6.3.1 Europe narcolepsy therapeutics market, 2014 - 2025 (USD Million)
               6.4 Asia Pacific
                   6.4.1 Asia Pacific narcolepsy therapeutics market, 2014 - 2025 (USD Million)
               6.5 Latin America
                   6.5.1 Latin America narcolepsy therapeutics market, 2014 - 2025 (USD Million)
               6.6 MEA
                   6.6.1 MEA narcolepsy therapeutics market, 2014 - 2025 (USD Million)
Chapter 7 Competitive Landscape
               7.1 Strategy framework
               7.2 Company Profiles
                   7.2.1 Addrenex Pharmaceuticals, Inc.
                       7.2.1.1 Company Overview
                       7.2.1.2 Product benchmarking
                       7.2.1.3 Strategic initiatives
                   7.2.2 Teva Pharmaceutical Industries Ltd.
                       7.2.2.1 Company overview
                       7.2.2.1 Financial performance
                       7.2.2.2 Product benchmarking
                       7.2.2.3 Strategic initiatives
                   7.2.3 Jazz Pharmaceuticals PLC
                       7.2.3.1 Company overview
                       7.2.3.2 Product benchmarking
                       7.2.3.3 Strategic initiatives
                   7.2.4 Graymark Healthcare, Inc.
                       7.2.4.1 Company overview
                       7.2.4.2 Product benchmarking
                       7.2.4.3 Strategic initiatives
                   7.2.5 Arena Pharmaceuticals, Inc.
                       7.2.5.1 Company overview
                       7.2.5.2 Financial performance
                       7.2.5.3 Product benchmarking
                       7.2.5.4 Strategic Initiatives
                   7.2.6 BIOPROJET
                       7.2.6.1 Company overview
                       7.2.6.2 Product benchmarking
                       7.2.6.3 Strategic initiatives
                   7.2.7 Shire
                       7.2.7.1 Company overview
                       7.2.7.2 Financial performance
                       7.2.7.3 Product benchmarking
                       7.2.7.4 Strategic initiatives
                   7.2.8 Ligand Pharmaceuticals, Inc.
                       7.2.8.1 Company overview
                       7.2.8.2 Financial performance
                       7.2.8.3 Product benchmarking
                       7.2.8.4 Strategic initiatives